DC AMS Pharma

What DC AMS Pharma does

DC AMS Pharma (东诚安迪科) is a Chinese radiopharmaceutical solutions provider operating as a wholly-owned subsidiary of Dongcheng Pharmaceutical Co., Ltd. (东诚药业, SZ002675), a Shenzhen Stock Exchange-listed company. Founded in Hong Kong in 1999 and acquired by Dongcheng Pharmaceutical in 2018, the company is headquartered in Nanjing, Jiangsu Province, with legal entity Nanjing Jiangyuan Andike Positive Electron Research Development Co., Ltd. (南京江原安迪科正电子研究发展有限公司). It serves hospital nuclear medicine departments and medical institutions across China, providing both radiopharmaceutical products (primarily 18F-FDG injection for PET imaging and Technetium [99mTc] Exametazime) and cyclotron-based production infrastructure under a Design-Build-Operate (DBO) service model.

The company's core technology integrates Japanese Sumitomo Heavy Industries medical cyclotrons with chemical synthesis modules, radiation monitoring systems, quality control systems, hot cells, and ancillary facilities to enable complete turnkey radiopharmaceutical production. It operates a proprietary AMStrac® service platform underpinned by a Six-Management-System framework covering radiation safety, drug production, drug quality, R&D, customer service, and network distribution management. The network comprises nearly 30 GMP-compliant production and distribution centers covering all major Chinese regions (East, North, Central, South, Northwest, Southeast, and Northeast China).

DC AMS Pharma generates revenue through three principal streams: (1) sale of short-lived and long-lived radiopharmaceutical products (notably 18F-FDG injection) to hospital nuclear medicine departments via its distribution network; (2) Cyclotron DBO services providing design, facility construction, equipment integration, and ongoing operational management for medical institutions, having served over 60 domestic customers; and (3) recurring network-based supply contracts enabled by the nationwide production-distribution infrastructure. Pricing is B2B and quotation-based rather than publicly disclosed. The go-to-market motion is enterprise field sales with direct institutional engagement, supported by regional profit centers and customer service teams providing nationwide coverage. The company holds multiple government certifications including High-Tech Enterprise status and Nanjing Radioactive Drug Engineering Technology Research Center designation.

Name

DC AMS Pharma

Legal name

南京江原安迪科正电子研究发展有限公司

Website

https://pet-tracer.com.cn

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

1–10 employees

Short description

DC AMS Pharma is a Chinese radiopharmaceutical solutions provider and wholly-owned subsidiary of Dongcheng Pharmaceutical (SZ002675), supplying PET tracers (notably 18F-FDG) and cyclotron Design-Build-Operate services to hospital nuclear medicine departments across China through a network of nearly 30 production-distribution centers.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE)

akta.pro secondary industries

Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF), Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Radiopharmaceutical production
• PET tracer supply
• Cyclotron DBO solutions
• Nuclear medicine distribution
• Medical imaging agents

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Infrastructure, Supply Chain, Technology or R&D, Personnel, Operations

Revenue model

1. Radiopharmaceutical Sales: Sale of radiopharmaceutical products including 18F-FDG injection and other PET tracers through a nationwide network of production and distribution centers. Products are delivered to hospitals and nuclear medicine departments for clinical diagnostic use.
2. Cyclotron DBO (Design-Build-Operate) Services: Turnkey solutions for cyclotron installation, facility construction, and ongoing operation management. Served over 60 domestic customers with cyclotron systems and DBO services, providing design, building, and operational support for PET tracer production facilities.
3. Radiopharmaceutical Production & Distribution Network: Networked production and distribution of short-lived and long-lived radiopharmaceuticals across China through nearly 30 GMP-compliant production and distribution centers, enabling scalable, industrialized supply.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

DC AMS Pharma manufactures and distributes short-lived radiopharmaceutical products, principally 18F-FDG injection for PET molecular imaging diagnostics, through a nationwide GMP-compliant network of ~30 production and distribution centers. The company also delivers turnkey Cyclotron DBO (Design-Build-Operate) solutions that integrate Sumitomo Heavy Industries medical cyclotrons with synthesis modules, radiation monitoring systems, quality control systems, and hot cells, enabling hospital and medical institutions to establish and operate PET radiopharmaceutical production facilities. The proprietary AMStrac® service platform underpins both product lines, supported by a Six-Management-System framework covering radiation safety, production, quality, R&D, customer service, and network distribution.

Product overview

DC AMS Pharma (东诚安迪科) operates as a subsidiary of East China Pharmaceutical (SZ002675), providing comprehensive radiopharmaceutical solutions for nuclear medicine. The company offers two core product lines: (1) radiopharmaceuticals including 18F-FDG injection for PET imaging, and (2) cyclotron DBO (Design-Build-Operate) solutions using Sumitomo medical cyclotrons integrated with synthesis modules, quality control systems, and hot cells. The AMStrac® service platform supports the radiopharmaceutical network system with six management systems covering radiation safety, production, quality, R&D, customer service, and distribution. The company has established nearly 30 production and distribution centers across China, serving over 60 customers with cyclotron systems and DBO services.

Differentiator

Problem solved

Functional benefit

Brands

• AMStrac®: 放射性药品网络化供应体系服务品牌，提供放射性药品生产和质量的全面解决方案 (Radioactive pharmaceutical network supply system service brand, providing comprehensive solutions for radioactive drug production and quality)
• DBO Solution

Products and services

• 18F-FDG Injection (18F-FDG注射液) A positron emission tomography (PET) radiopharmaceutical tracer used for molecular imaging diagnostics. 18F-FDG (fluorodeoxyglucose) is a radioactive glucose analog used to detect metabolic activity in tissues, primarily for oncology, cardiology, and neurology diagnostic imaging, supplied to hospital nuclear medicine departments through DC AMS Pharma's GMP-compliant production and distribution network.
• Cyclotron DBO Solution (回旋加速器DBO解决方案) Turnkey cyclotron-based solution providing Design, Building, and Operation services for positron radiopharmaceutical production centers, integrating Sumitomo Heavy Industries medical cyclotron with chemical synthesis modules, radiation monitoring systems, quality control systems, hot cells, and auxiliary facilities. Served over 60 domestic customers with cyclotron systems and DBO services.
• AMStrac® Service (AMStrac®服务) Professional service platform providing comprehensive solutions for radiopharmaceutical production and quality management, part of the radiopharmaceutical network system enabling standardized, networked, scaled, and industrialized production and distribution of short-lived and long-lived radiopharmaceuticals across China.
• Technetium [99mTc] Exametazime for Injection (注射用亚锡双半胱氨酸) A radiopharmaceutical product (1.0mg Bicicate and 0.1mg stannous chloride per vial for single-use preparation) manufactured by subsidiary Beijing Xinkesida Pharmaceutical Technology Co., Ltd., historically supplied for clinical nuclear medicine procedures and subject to a Class 3 recall on batches 250909, 251003, 251008, and 251101 in January 2026 due to individual test abnormalities.

Quantifiable outcome

• Network covers all major regions of China with ~30 production and distribution centers
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Jiangsu Provincial Government (江苏省委)minorOthers · 12 February 2025Jiangsu Provincial Party Secretary Xin Changxing visited the company's Nanjing facility on February 12-13, 2025 as part of an investigation into the bio-pharmaceutical industrial cluster. The provincial government expressed support for nuclear medicine development, encouraging the company to develop new drugs and high-end diagnostic equipment.
• Shanghai Municipal Ecological Environment Bureau (上海市生态环境局)minorOthers · 24 April 2019Deputy Director Su Guodong led an on-site research visit to Shanghai Andike Positive Electron Technology in April 2019 to understand the company's radiation safety management and gather feedback on government management and services. The bureau expressed support for the company's expansion plans in Shanghai.
• Sumitomo Heavy Industries (日本住友重工)coreTechnology or IntegrationDC AMS Pharma uses Sumitomo Heavy Industries医用回旋加速器 (medical cyclotron) as the core component of its cyclotron DBO solutions. This is the foundational technology partnership enabling the company's turnkey cyclotron system offerings to domestic customers.
• Dongcheng Pharmaceutical Group (东诚药业 SZ002675)coreStrategic or Co-development PartnerDongcheng Andike is a wholly-owned subsidiary of Dongcheng Pharmaceutical (SZ002675), acquired in 2018. The company operates as the core nuclear medicine business unit of Dongcheng Pharmaceutical, which is a Shenzhen Stock Exchange listed company. The subsidiary contributes to the group's nuclear medicine segment strategy.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Siemens Healthineers: Major manufacturer of PET/CT systems and operator of cyclotron-based radiopharmaceutical production for FDG and other tracers. Comparable to DC AMS Pharma in serving hospital nuclear medicine customers with both imaging hardware and tracer supply.
• Novartis (Advanced Accelerator Applications): Through its AAA division, Novartis is a global leader in radioligand therapy and PET diagnostics (e.g., Lutathera, NETSPOT). Comparable to DC AMS Pharma as a vertically integrated player in nuclear medicine, though focused on theranostics rather than broad PET tracer supply.
• GE HealthCare: Global leader in PET/CT scanners and a significant producer of PET radiopharmaceuticals through its pharmaceutical diagnostics segment. Directly comparable to DC AMS Pharma as a vertically integrated supplier of imaging equipment and tracers for hospital nuclear medicine departments.
• Philips Healthcare: Provides PET imaging solutions and adjacent radiopharmaceutical services globally. Comparable as a broad incumbent serving nuclear medicine departments with imaging systems that consume PET tracers similar to those DC AMS Pharma produces.
• Bayer (Curium partnership / Radiology): Bayer's radiology business and prior joint venture with Curium covers contrast media and radiopharmaceuticals. Comparable as a broad incumbent in the medical imaging and nuclear medicine supply chain adjacent to DC AMS Pharma's core offerings.

Direct peers

• Lantheus Holdings: U.S.-based radiopharmaceutical company focused on diagnostic imaging agents including PET tracers and SPECT products. Comparable business model to DC AMS Pharma's radiopharmaceutical production and distribution for hospital nuclear medicine.
• China Isotope & Radiation Corporation (CIRC): Chinese state-backed producer and distributor of radioisotopes and radiopharmaceuticals for medical and industrial use. The closest direct domestic peer to DC AMS Pharma, operating a comparable China-wide network of radiopharmaceutical production and distribution.
• Curium Pharma: Global nuclear medicine company producing SPECT and PET radiopharmaceuticals with vertically integrated manufacturing and distribution. Directly comparable to DC AMS Pharma in the radiopharmaceutical CDMO and distribution space.
• Sinotau Pharmaceutical Group: China-based radiopharmaceutical company specializing in PET tracer production and molecular imaging diagnostics. Directly competes with DC AMS Pharma in the 18F-FDG and PET radiopharmaceutical market in China.

Emerging players

• IBA (Ion Beam Applications): Belgian supplier of cyclotrons and radiopharma production solutions for hospital and industrial customers. Directly comparable to DC AMS Pharma's cyclotron DBO offering and competes with Sumitomo in the medical cyclotron market DC AMS Pharma relies on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DC AMS Pharma